Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03321981
Title MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Merus N.V.

Her2-receptor positive breast cancer

estrogen-receptor positive breast cancer


Letrozole + Zenocutuzumab

Anastrozole + Zenocutuzumab

Fulvestrant + Zenocutuzumab

Exemestane + Zenocutuzumab

Trastuzumab + Zenocutuzumab

Trastuzumab + Vinorelbine + Zenocutuzumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | BEL

No variant requirements are available.